On Health Policy Archives

Letter to Senator Warren Thanking Her and Other Women Senators for Urging FDA Commissioner Hamburg to Improve Representation in Clinical Research

May 8, 2014. We thanked 15 women Senators for urging FDA Commissioner Margaret Hamburg to improve the representation of women and minorities in clinical research.

Coalition Comments to FDA Urging Stronger FDA Guidelines on Drug Ads

May 2, 2014. We strongly oppose the guidance. These guidelines are aimed at clarifying guidelines developed before the law regarding distributing scientific and medical publications on unapproved new uses (off-label) of medical products sunset in 2006. It fails to follow the law or to protect patients and the public health.

Coalition Comments to FDA on Direct-To-Consumer Prescription Drug Television Advertisements

April 21, 2014. Members of the Patient, Consumer, and Public Health Coalition applaud FDA’s efforts to clearly and effectively communicate risks and benefits to consumers in direct-to-consumer (DTC) advertisements.

NCHR Comment on the Importance of Including Women, Minorities, and the Elderly in Studies for New Drugs and Devices (FDASIA Section 907 Hearing)

April 1, 2014. The responsibility of collecting sufficiently representative demographic subgroup data sits solely on the shoulders of device and drug companies. The companies know how to persuade – they do it everyday in commercials. Similarly, if they identify persuasive incentives for patients to participate in studies, and minimize disincentives, patients will participate and be available for follow-up.

Letter to Representative Slaughter in Strong Support of H.R. 1150, the Preservation of Antibiotics for Medical Treatment Act

March 21, 2014. As members of the Patient, Consumer, and Public Health Coalition, we strongly support H.R. 1150, the Preservation of Antibiotics for Medical Treatment Act.